Most Favored Patient Act of 2026

This bill requires drug manufacturers to offer Medicare Part D and Part B patients the lowest price they charge in eight specific countries (Canada, Denmark, France, Germany, Italy, Japan, Switzerland, UK), defined as the "most-favored-nation price." It directly affects drug manufacturers not in a special agreement with Medicare and Medicare beneficiaries who use covered drugs. The model, tested for five years starting in 2029, mandates manufacturers to report pricing data and provide discounts to eligible patients and providers. Manufacturers could avoid the requirement by signing an agreement with Medicare before December 2028. The bill aims to align U.S. drug prices with international averages for certain Medicare-covered drugs.